Ophthalmology

Latest News

Latest Videos

David Boyer, MD, on Potential Advantages of Suprachoroidal Gene Therapy for Neovascular AMD

Dilsher Dhoot, MD, On Reducing Treatment Burden in Diabetic Retinopathy With Gene Therapy

Magdalena Cichewicz, PhD, on Improving AAV Gene Therapy With Synthetic Promoters

Arshad Khanani, MD, on Future Plans for anti-VEGF Gene Therapy 4D-150

Arshad Khanani, MD, on 4D-150’s Ability to Address Treatment Burden in Wet AMD

Bart P. Leroy, MD, PhD, on Aligning IRD Gene Therapy Outcome Measures With Activities of Daily Living

Bart P. Leroy, MD, PhD, on Improving Light Sensitivity, Quality of Life With Luxturna

Jay Barth, MD, on Ascidian Therapeutics' Developments in Gene Therapy

Arnaud Lacoste, PhD, on AURN001‘s Immunomodulatory Properties

Bart P. Leroy, MD, PhD, on Continuing to Verify Luxturna’s Efficacy

CME Content

$New Horizons in Multiple Myeloma Treatment – Selection and Sequencing From Newly Diagnosed to Relapsed/Refractory Disease$

Video

New Horizons in Multiple Myeloma Treatment – Selection and Sequencing From Newly Diagnosed to Relapsed/Refractory Disease

Amrita Krishnan, MD; Suzanne Lentzsch, MD, PhD; Sagar Lonial, MD, FACP

Multimedia

Exploring the Dynamic Shifts in the MDS Treatment Paradigm: Unveiling Advances in Disease Modifying Therapies, Spotlight on Cutting-Edge Clinical Trials, and the Latest Approvals

Amer Zeidan, MBBS, MHS; Michael R. Savona, MD

Video

Medical Crossfire®: Uncovering The Clinical Utility of Combination Therapies and MRD Assessment in Newly Diagnosed Multiple Myeloma

Ajai Chari, MD; Adriana Rossi, MD; Anupama Kumar, MD

Multimedia

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

Corey Cutler, MD, MPH, FRCP(C); Carrie L. Kitko, MD

Multimedia

Community Practice Connections™: 8th Annual School of Nursing Oncology™

Beth Sandy, MSN, CRNP, FAPO; Laura Wood, RN, MSN, OCN; Michael Lai, ARNP; Tiffany Richards, PhD, ANP-BC, AOCNP®; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Megan Wanca, APRN, DNP, FNP-C

Case-based Simulation

SimulatEd™: Patient-Centered Care to Improve Outcomes in Chronic Lymphocytic Leukemia

Catherine C. Coombs, MD

Video

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

Video

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

Multimedia

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD

Video

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Eytan M. Stein, MD; Marina Kremyanskaya, MD, PhD; Hannah Levavi, MD

Video

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Rami Komrokji, MD; Maen Hussein, MD

In-Person + Virtual Event

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

December 5, 2025

Video

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

Craig Emmitt Cole, MD; Sikander Ailawadhi, MD; Irene Ghobrial, MD; Monique Hartley-Brown, MD, MMSc

Multimedia

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

Elias Jabbour, MD

Video

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Cristina Gasparetto, MD; Katja Weisel, MD

Video

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

Rami S. Komrokji, MD; Ghaith Abu-Zeinah, MD; Gabriela Hobbs, MD; Barbara Mora, MD

Video

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Krina Patel, MD, MSc; Alfred L. Garfall, MD; Ajay K. Nooka, MD, MPH, FACP

Video

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Corey Cutler, MD, MPH, FRCPC; Amin M. Alousi, MD; Yi-Bin Chen, MD; Carrie Lynn Kitko, MD

Video

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Alexey V. Danilov, MD, PhD; Leidy L. Isenalumhe, MD, MS; Lori A. Leslie, MD; Mazyar Shadman, MD, MPH; Jason R. Westin, MD, MS, FACP

Video

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Elias Jabbour, MD; Hagop M. Kantarjian, MD; Aaron Logan, MD, PhD, MPhil; Rob Pieters, MD, PhD; Claire Roddie, MD, PhD

Case-based Simulation

SimulatEd™ in Multiple Myeloma: Personalizing Care Plans to Treat Newly Diagnosed Patients

Amrita Krishnan, MD

In-Person Event

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

February 26-28, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Video

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

André H. Goy, MD; Jorge E. Cortes, MD; Sagar Lonial, MD, FACP

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

In-Person Event

10th Annual Live Medical Crossfire®: Hematologic Malignancies

July 11, 2026

Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Amrita Krishnan, MD; Meletios Athanasios (Thanos) C. Dimopoulos, MD; Shaji Kumar, MD; Katja Weisel, MD

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

In-Person + Virtual Event

Go To PER in Chicago

On-Demand Sessions Available Now!

More News

Nanoscope Therapeutics’ Gene Therapy MCO-010 Restores Vision in Patients With Retinitis Pigmentosa

ByMartin Harp

April 4th 2025

At 12 weeks posttreatment, all 4 of the patients showed improvement in the form of a lower logMAR.

Around the Helix: Cell and Gene Therapy Company Updates – April 2, 2025

ByNoah Stansfield

April 2nd 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Data Roundup: March 2025 Features Updates from MDA's Conference, an Alzheimer Disease Trial, and More

ByNoah Stansfield

April 1st 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

ByNoah Stansfield

April 1st 2025

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

ByNoah Stansfield

March 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Genetic and Gender Factors Linked to Fuchs Endothelial Corneal Dystrophy in University College London Study

ByHattie Hayes

March 25th 2025

These findings could support gene therapies targeting CTG18.1 that are currently in development.

Around the Helix: Cell and Gene Therapy Company Updates – March 19, 2025

ByNoah Stansfield

March 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

SpliceBio Doses First Patient in Trial for Stargardt Gene Therapy SB-007

ByHattie Hayes

March 16th 2025

The ASTRA and accompanying POLARIS studies are actively enrolling patients.

Around the Helix: Cell and Gene Therapy Company Updates – March 12, 2025

ByNoah Stansfield

March 12th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

ByJoseph A. Fraietta, PhD,Janna Minehart, MD,Noah Stansfield,Matt Hoffman

March 11th 2025

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.

Stem Cell Therapy CALEC Restores Corneal Damage in Trial Led by Massachusetts Eye and Ear Investigators

ByLynda Charters

March 7th 2025

CALEC completely restored the cornea in 50% of participants at their 3-month visit and that rate of complete success increased to 79% and 77% at their 12- and 18-month visits, respectively.

Data Roundup: February 2025 Features Updates from WORLDSymposium, Tandem Meetings, and More

ByCGTLive Staff

March 6th 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Neurotech’s Encapsulated Cell Therapy Encelto Approved by FDA for Macular Telangiectasia Type 2

ByNoah Stansfield

March 6th 2025

Neurotech expects that the therapy will become available in the United States in June 2025.

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025

ByNoah Stansfield

March 5th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Ocugen’s Geographic Atrophy and Stargardt Gene Therapies Garner Positive ATMP Opinions from EMA

ByHattie Hayes

March 5th 2025

According to Ocugen, the EMA has granted OCU410 and OCU410ST Advanced Therapy Medicinal Product classification.

FDA Activity Recap: February 2025 Features Multiple BLA Acceptances, RMAT Designations, and More

ByCGTLive Staff

March 2nd 2025

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Around the Helix: Cell and Gene Therapy Company Updates – February 26, 2025

ByNoah Stansfield

February 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 19, 2025

ByNoah Stansfield

February 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 12, 2025

ByNoah Stansfield

February 12th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 5, 2025

ByNoah Stansfield

February 5th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Data Roundup: January 2025 Features Updates for Sarepta's Elevidys in DMD, Tenaya's Hypertrophic Cardiomyopathy Gene Therapy, and More

ByCGTLive Staff

February 3rd 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

FDA Activity Recap: January 2025 Features CRL, Multiple Clinical Holds, and More

ByCGTLive Staff

February 2nd 2025

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

ImmunoLogic, Episode 1: "Chemo-Free Lymphoma? Seriously?" With Stephen J. Schuster, MD

ByJoseph A. Fraietta, PhD,Janna Minehart, MD,Noah Stansfield,Matt Hoffman

January 31st 2025

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

Around the Helix: Cell and Gene Therapy Company Updates – January 29, 2025

ByNoah Stansfield

January 29th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – January 22, 2025

ByNoah Stansfield

January 22nd 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Ophthalmology

Latest News

Latest Videos

David Boyer, MD, on Potential Advantages of Suprachoroidal Gene Therapy for Neovascular AMD

Dilsher Dhoot, MD, On Reducing Treatment Burden in Diabetic Retinopathy With Gene Therapy

Magdalena Cichewicz, PhD, on Improving AAV Gene Therapy With Synthetic Promoters

Arshad Khanani, MD, on Future Plans for anti-VEGF Gene Therapy 4D-150

Arshad Khanani, MD, on 4D-150’s Ability to Address Treatment Burden in Wet AMD

Bart P. Leroy, MD, PhD, on Aligning IRD Gene Therapy Outcome Measures With Activities of Daily Living

Bart P. Leroy, MD, PhD, on Improving Light Sensitivity, Quality of Life With Luxturna

Jay Barth, MD, on Ascidian Therapeutics' Developments in Gene Therapy

Arnaud Lacoste, PhD, on AURN001‘s Immunomodulatory Properties

Bart P. Leroy, MD, PhD, on Continuing to Verify Luxturna’s Efficacy

CME Content

New Horizons in Multiple Myeloma Treatment – Selection and Sequencing From Newly Diagnosed to Relapsed/Refractory Disease

Exploring the Dynamic Shifts in the MDS Treatment Paradigm: Unveiling Advances in Disease Modifying Therapies, Spotlight on Cutting-Edge Clinical Trials, and the Latest Approvals

Medical Crossfire®: Uncovering The Clinical Utility of Combination Therapies and MRD Assessment in Newly Diagnosed Multiple Myeloma

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

Community Practice Connections™: 8th Annual School of Nursing Oncology™

SimulatEd™: Patient-Centered Care to Improve Outcomes in Chronic Lymphocytic Leukemia

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

SimulatEd™ in Multiple Myeloma: Personalizing Care Plans to Treat Newly Diagnosed Patients

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Go To PER in Chicago

More News

Nanoscope Therapeutics’ Gene Therapy MCO-010 Restores Vision in Patients With Retinitis Pigmentosa

Around the Helix: Cell and Gene Therapy Company Updates – April 2, 2025

Data Roundup: March 2025 Features Updates from MDA's Conference, an Alzheimer Disease Trial, and More

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

Genetic and Gender Factors Linked to Fuchs Endothelial Corneal Dystrophy in University College London Study

Around the Helix: Cell and Gene Therapy Company Updates – March 19, 2025

SpliceBio Doses First Patient in Trial for Stargardt Gene Therapy SB-007

Around the Helix: Cell and Gene Therapy Company Updates – March 12, 2025

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

Stem Cell Therapy CALEC Restores Corneal Damage in Trial Led by Massachusetts Eye and Ear Investigators

Data Roundup: February 2025 Features Updates from WORLDSymposium, Tandem Meetings, and More

Neurotech’s Encapsulated Cell Therapy Encelto Approved by FDA for Macular Telangiectasia Type 2

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025

Ocugen’s Geographic Atrophy and Stargardt Gene Therapies Garner Positive ATMP Opinions from EMA

FDA Activity Recap: February 2025 Features Multiple BLA Acceptances, RMAT Designations, and More

Around the Helix: Cell and Gene Therapy Company Updates – February 26, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 19, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 12, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 5, 2025

Data Roundup: January 2025 Features Updates for Sarepta's Elevidys in DMD, Tenaya's Hypertrophic Cardiomyopathy Gene Therapy, and More

FDA Activity Recap: January 2025 Features CRL, Multiple Clinical Holds, and More

ImmunoLogic, Episode 1: "Chemo-Free Lymphoma? Seriously?" With Stephen J. Schuster, MD

Around the Helix: Cell and Gene Therapy Company Updates – January 29, 2025

Around the Helix: Cell and Gene Therapy Company Updates – January 22, 2025

Trending on CGTlive®

Ultragenyx's Glycogen Storage Disease Gene Therapy DTX401 Continues to Enable Decreases in Reductions in Daily Cornstarch Intake at 96 Weeks

Sanofi’s Neovascular Age-Related Macular Degeneration Gene Therapy SAR402663 Garners FDA Fast Track Designation

ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”